Published: September 28, 2016

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy.

Published: August 23, 2016

On Saturday, September 17, the CCTG Trialblazers participated in the Canadian Cancer Society's Mudmoiselle Ladies' Mud Run held in Kingston. They raised over $2500 and had a blast doing it!

We would like to thank the Trialblazers team for their team spirit and willingness to get down and dirty in support of cancer research.

Published: September 20, 2016

The Canadian Cancer Trials Group was referenced in an articles on funds raised for brain cancer research by The Tragically Hip's summer tour.

Published: July 14, 2016

Dr. Chris O'Callaghan, at the Canadian Cancer Trials Group in Kingston, is a senior investigator in a new trial that produced effective results in improving the longevity and quality of life of patients with glioblastoma, an incurable brain cancer.

Published: June 08, 2016

Two cancer trials conducted by the Queen’s University-based Canadian Cancer Trials Group (CCTG) and lead scientific investigators Chris O’Callaghan and Wendy Parulekar have been recognized as among the highest impact studies in the world.

Published: June 06, 2016

A unique partnership between the Canadian Cancer Trials Group and the 7 Days in May Foundation has resulted in over $145,000 being raised for the PA.6 pancreatic cancer trial. This is the fourth year the Foundation has organized a seven-day bike ride around Lake Ontario, 7 Days in May, to raise money for pancreatic cancer research, and the third time it has donated the proceeds to the Canadian Cancer Trials Group.

Published: April 18, 2016

The Canadian Cancer Society's online support group, Cancer will be hosting a webcast on Tuesday, April 19 at 6pm (Eastern time). The topic for this webcast is Clinical Trials 101.

Published: March 09, 2016

MA.36 (OlympiA) trial: A Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.

Published: December 07, 2015

Dr. Kim Chi, Co-Chair of Canadian Cancer Trials Group's Genitourinary Site Committee and medical oncologist at the British Columbia Cancer Agency in Vancouver, has been awarded $500,000 from the Canadian Cancer Clinical Trials Network (3CTN) for the support of an exciting new IND Program suite of trials in castrate resistant prostate cancer, "Precision Oncology Platform for Prostate Cancer: A Phase 2 Umbrella Trial for Patients with Metastatic Castration Resistant Prostate Cancer."

Published: November 18, 2015

You are invited to join the Canadian Cancer Society’s exclusive Telephone Town Hall, where a panel of experts will bring the world of clinical trials to life and explain how clinical trials are improving cancer prevention, detection and treatment.